University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Takeru Wakatsuki , Wu Zhang , Dongyun Yang , Fotios Loupakis , Mizutomo Azuma , Armin Gerger , Francesco Graziano , Yan Ning , Melissa Janae Labonte , Rita El-Khoueiry , Pierre Oliver Bohanes , Leonor Benhaim , David Páez , Masahiko Watanabe , Wasaburo Koizumi , Heinz-Josef Lenz
Training set |
Validation set |
|||||||
---|---|---|---|---|---|---|---|---|
Cau (%) | Hisp (%) | Jap (%) | P value | Cau (%) | Hisp (%) | Jap (%) | P value | |
VEGFR2 rs12505758 T/C | 84.0 | 85.0 | 68.8 | 0.009 | 87.0 | 83.3 | 64.3 | 0.004 |
VEGFR1 rs9582036 C/A | 79.0 | 86.0 | 82.7 | 0.660 | 75.0 | 80.0 | 83.0 | 0.740 |
VEGF-A rs699946 A/G | 78.0 | 60.2 | 49.0 | 0.001 | 78.0 | 76.0 | 58.0 | 0.021 |
VEGFR2 rs11133360 C/T | 55.1 | 43.8 | 70.8 | 0.002 | 60.0 | 35.9 | 68.0 | <0.001 |
VEGF-A rs833061 C/T | 52.0 | 35.0 | 29.6 | 0.020 | 50.0 | 40.0 | 33.0 | 0.200 |
VEGF-A rs699947 A/C | 51.0 | 34.0 | 27.6 | 0.013 | 51.0 | 36.0 | 29.0 | 0.026 |
VEGF-A rs1570366 A/G | 39.0 | 17.0 | 14.6 | 0.001 | 37.0 | 22.0 | 20.4 | 0.130 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Chun-Wei Pan
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Masatoshi Kudo
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Julien Taieb